急性冠脉综合征后初始及连续C反应蛋白水平与不良心血管事件及死亡的相关性:VISTA-16试验二次分析
该研究为VISTA-16随机双盲试验的二次分析,纳入4257例急性冠脉综合征患者,在16周内多次测量高敏C反应蛋白(hsCRP)。多变量分析显示,基线和纵向hsCRP升高均与主要不良心脏事件(MACE)、心血管死亡和全因死亡独立相关,提示系列hsCRP监测有助于识别高危患者。
要点
- ACS后16周内基线和纵向hsCRP升高均独立增加MACE风险。
- 纵向hsCRP每升高1个标准差,心血管死亡风险增加26%。
- 系列hsCRP监测可能帮助识别ACS后死亡和发病高危患者。
核心结论
- ACS后16周内初始和后续hsCRP升高与MACE、心血管死亡和全因死亡风险增加相关,且独立于背景治疗。
研究设计与样本
- VISTA-16试验的二次分析,该试验为双盲、多中心、随机临床试验,纳入5145例ACS患者,本分析评估4257例有基线和纵向hsCRP数据的患者。
关键数值与推荐
- 中位16周低密度脂蛋白胆固醇水平为64.9 mg/dL(IQR 50.3-82.3 mg/dL)。
- 中位hsCRP水平为2.4 mg/L(IQR 1.1-5.2 mg/L)。
临床怎么用
- ACS后临床随访中系列测量hsCRP可能有助于识别死亡和发病高危患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Higher baseline high-sensitivity C-reactive protein (hsCRP) levels after an acute coronary syndrome (ACS) are associated with adverse cardiovascular outcomes. The usefulness of serial hsCRP measurements for risk stratifying patients after ACS is not well characterized. OBJECTIVE: To assess whether longitudinal increases in hsCRP measurements during the 16 weeks after ACS are independently associated with a greater risk of a major adverse cardiac event (MACE), all-cause death, and cardiovascular death. DESIGN, SETTING, AND PARTICIPANTS: Secondary analysis of the double-blind, multicenter, randomized clinical Vascular Inflammation Suppression to Treat Acute Coronary Syndromes for 16 Weeks (VISTA-16) trial conducted between June 1, 2010, and March 7, 2012 (study termination on March 9, 2012), which included 5145 patients from 362 academic and community hospitals in Europe, Australia, New Zealand, India, and North America assigned to receive varespladib or placebo on a background of atorvastatin treatment beginning within 96 hours of presentation with an ACS. The present study evaluated data from patients with available baseline and longitudinal hsCRP levels measured at weeks 1, 2, 4, 8, and 16 after randomization to treatment or placebo. Statistical analysis was performed from June 15, 2018, through September 15, 2018. MAIN OUTCOMES AND MEASURES: Outcomes were MACE (composite of cardiovascular death, myocardial infarction, nonfatal stroke, or unstable angina with documented ischemia requiring hospitalization), cardiovascular death, and all-cause death after adjustment for baseline clinical, treatment, and laboratory characteristics, including baseline hsCRP levels. RESULTS: Among 4257 patients in this study, 3141 (73.8%) were men and the mean age was 60.3 years (interquartile range [IQR], 53.5-67.8 years). The median 16-week low-density lipoprotein cholesterol level was 64.9 mg/dL (IQR, 50.3-82.3 mg/dL), and the median hsCRP level was 2.4 mg/L (IQR, 1.1-5.2 mg/L). On multivariable analysis, higher baseline hsCRP level (hazard ratio [HR], 1.36 [95% CI, 1.13-1.63]; P = .001) and higher longitudinal hsCRP level (HR, 1.15 [95% CI, 1.09-1.21]; P < .001) were independently associated with MACE. Similar significant and independent associations were shown between baseline and longitudinal hsCRP levels and cardiovascular death (baseline: HR, 1.61 per SD [95% CI, 1.07-2.41], P = .02; longitudinal: HR, 1.26 per SD [95% CI, 1.19-1.34], P < .001) and between baseline and longitudinal hsCRP levels and all-cause death (baseline: HR, 1.58 per SD [95% CI, 1.07-2.35], P = .02; longitudinal: HR, 1.25 per SD [95% CI, 1.18-1.32], P < .001). CONCLUSIONS AND RELEVANCE: Initial and subsequent increases in hsCRP levels during 16 weeks after ACS were associated with a greater risk of the combined MACE end point, cardiovascular death, and all-cause death despite established background therapies. Serial measurements of hsCRP during clinical follow-up after ACS may help to identify patients at higher risk for mortality and morbidity.
引用
- Mani P, Puri R, Schwartz GG, et al. Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome: A Secondary Analysis of the VISTA-16 Trial. JAMA Cardiol. 2019. PMID: 30840024. doi:10.1001/jamacardio.2019.0179
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。